GlobeNewswire

Genomatica brings its naturally sourced Brontide(TM) butylene glycol to Europe

Dela

Azelis chosen to distribute; already confirming better personal care formulations

SAN DIEGO and ANTWERP, Belgium, March 20, 2018 (GLOBE NEWSWIRE) -- Genomatica, a widely-recognized technology leader for naturally sourced chemicals, and Azelis, a leading distributor of specialty chemicals, announced that Azelis is now the exclusive distributor for personal care applications of Genomatica's naturally sourced, award-winning Brontide(TM) butylene glycol in Europe. Azelis is already seeing widespread interest in Brontide from major brands and plans to support scores of major customers during Brontide's market introduction. See Brontide introduction video.

Photos accompanying this announcement are available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/689e9f6d-b2ba-4977-ac51-3a74b9e6fba9

http://www.globenewswire.com/NewsRoom/AttachmentNg/7baf9c6b-8b96-4326-8049-a57d4c22a177

A naturally sourced, sustainable cosmetics ingredient; Brontide honored for innovation

Butylene glycol, a colorless organic alcohol, is commonly used in a wide range of personal care products to increase moisture retention (as a humectant), improve texture, and provide antimicrobial properties. Additionally, it is used to evenly disperse plant extracts, flavors and fragrances.

Genomatica produces Brontide biobased butylene glycol from natural, plant-based sugars using its safe and sustainable fermentation-based process technology. This innovative approach has high appeal in personal care applications where demand for natural ingredients is growing. Brontide has already been recognized by the mainstream chemical industry with the prestigious ICIS Innovation Award.

Azelis actively developing formulations; sees strong customer interest

Azelis, a leading global specialty chemicals distributor with over 40,000 customers in 40 countries will provide sales, technical and logistics support for personal care product makers in Europe that are looking for a natural alternative to petroleum-based butylene glycol.

Azelis has also been actively developing and testing multiple personal care product formulations using Genomatica's Brontide, including hydra gels, body sprays, and sunscreens. These have tested well for key formulation attributes such as scent, viscosity, pH and stability.

Azelis reports that demand for natural ingredients has multiplied across its customer base. "We're already seeing strong interest in Genomatica's Brontide butylene glycol," said Tony Craske, Market Segment Director EMEA for Personal Care, Azelis. "Brontide is a perfect example of the new and exciting technologies that we deliver to our personal care partners. This naturally sourced, sustainable high-quality ingredient makes it easy for formulators and brands to improve their products."

"Azelis knows how to highlight the value of a great ingredient and help their customers benefit from it," said Damien Perriman, Genomatica's Senior Vice President, Specialty Chemicals. "Together, we can help make lots of everyday products better for people and the planet."

Genomatica has been producing and shipping tons of Brontide to customers since mid-2017. For samples, companies developing personal care products in Europe should contact Azelis at Brontide.BG@azelis.com; all others should contact Genomatica at Brontide@genomatica.com.

About Azelis

Azelis is a leading distributor of speciality chemicals and food ingredients present in over 40 countries across the globe with around 1,800 employees. Our knowledgeable teams of industry, market and technical experts are each dedicated to a specific market within Life Sciences and Industrial Chemicals. We offer a lateral value chain of complementary products to over 40,000 customers, creating a turnover of €1.8 billion. In the US we operate under a number of renowned co-brands that cater to the various markets in the region.

Throughout our extensive network of 39 application laboratories, our award-winning technical staff help customers develop formulations. We combine a global reach with a local focus to offer a reliable, integrated service to local customers and attractive business opportunities to principals. And we believe in building and nurturing solid, honest and transparent relationships with our people and partners.

Creating value, growing together. www.azelis.com

About Genomatica

Genomatica is a widely-recognized leader in bioengineering. It develops biobased process technologies that enable a better way to produce widely-used chemicals, from alternative feedstocks, with better economics, sustainability and performance. Genomatica has earned widespread acclaim for its technology and commercialization achievements. Awards include the Kirkpatrick Award, for "the most noteworthy chemical engineering technology commercialized in the world" and the ICIS Innovation Award for its Brontide(TM) butylene glycol. To learn more, visit www.genomatica.com

For more information

For Azelis: Marina Kaptein, +32 3 613 0125, marina.kaptein@azelis.com
For Genomatica: Patti Bianchi, CG Life, +1.630.841.1771, pbianchi@cglife.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Genomatica via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum